hVIVOOPORF +27.29%42 Buyback Yield % is -0.02 as of Jun. 30, 2026. GuruFocus rates OPORF with a GF Score™ of 42/100 and a GF Value™ of $0.25 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 88 Medical Diagnostics & Research companies, hVIVO ranks better than 61.36% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for hVIVO's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPORF vs TMO, DHR, IDXX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, hVIVO's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
hVIVO Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, hVIVO's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where hVIVO's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
hVIVO (OPORF) has a Buyback Yield % of -0.02 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on hVIVO and its competitors. According to the industry distribution chart, hVIVO ranks #34 out of 88 companies in the Medical Diagnostics & Research industry, placing it in the top 38.6%.
Is hVIVO's Buyback Yield % too high?
hVIVO's current Buyback Yield % is -0.02. Based on the distribution chart, hVIVO ranks #34 out of 88 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, hVIVO has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does hVIVO's Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, hVIVO ranks #34 out of 88 companies for Buyback Yield %. This puts hVIVO in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on hVIVO and its competitors. hVIVO's current Buyback Yield % is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is hVIVO stock overvalued right now?
Based on GuruFocus' analysis, hVIVO (OPORF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.25, compared to a current price of $0.11 — trading 56.2% below its estimated fair value. The current Buyback Yield % is -0.02. hVIVO's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For hVIVO (OPORF), the current Buyback Yield % is -0.02 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is hVIVO (OPORF) Overvalued in 2026?
Based on GuruFocus' analysis, hVIVO stock appears to be undervalued.
The current stock price of $0.11 is trading 56.2% below its estimated GF Value™ of $0.25.
GuruFocus considers hVIVO to be Possible Value Trap.
Key valuation signals for OPORF:
Buyback Yield %: -0.02
GF Value™: $0.25 vs. price of $0.11 (56.2% below fair value)
No single metric tells the full story. See the OPORF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
42GF Score
Get the complete analysis for OPORF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPORF has been successfully added to your 
